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Purpose: Active surveillance (AS) of low-risk papillary thyroid microcarcinoma (PTMC) 
may reduce the risk of overtreatment of clinically insignificant cancer. However, the absence of 
predictor for the progression of PTMC resulted in treatment delay and potentially compromis-
ing cure of aggressive disease. Therefore, to anticipate potential damage of delayed surgery, 
we investigated the oncologic outcomes of patients with low-risk PTMC initially eligible for 
AS except clinically apparent lymph node metastasis (LNM), imitating delayed surgery with 
neck dissection.
Materials and methods: A total of 5,348 patients, enrolled between 1987 and 2016, with 
low-risk PTMC initially eligible for AS were included regardless of LNM. We classified our 
study patients into two groups: Group I, lobectomy with prophylactic central cervical node 
dissection; Group II, total thyroidectomy with modified radical neck dissection for LNM. In 
addition, we investigated the oncological outcomes of patients with second-wave surgery due 
to lateral lymph node recurrence (Group III, subgroup of Group I).
Results: Group I showed more favorable clinicopathological characteristics compared with 
Group II. In Group I, only 29 (0.58%) of 4,927 patients underwent second-wave surgery with 
neck dissection for lateral lymph node recurrences, whereas in Group II, all 22 (5.23%) of 421 
patients underwent second-wave selective node dissection because of nodal recurrence. Disease-
free survival rates were significantly different between Groups I and II (P<0.05). Of note, the 
recurrence rate of Group II was still significantly higher than that of Group III (5.2% vs 0%, 
respectively; P=0.021). In addition, Kaplan–Mayer survival analysis indicated poor disease-free 
survival rates in Group II compared with Group III (P<0.05).
Conclusion: The long-term treatment outcome of PTMC without LNM was favorable even 
if the recurrence occurs during follow-up period compared with that of PTMC with LNM. It 
should be noted that AS might be able to cause poor prognosis due to clinically apparent LNM.
Keywords: active surveillance, papillary thyroid microcarcinoma, lymphatic metastasis, 
neoplasm recurrence
Introduction
Recent studies have suggested that active surveillance (AS) for carefully selected 
patients with low-risk localized papillary thyroid carcinoma (PTC), especially papil-
lary thyroid microcarcinoma (PTMC) ≤1 cm in maximum diameter, may reduce the 
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risk of overtreatment of clinically insignificant cancer.1,2 
Because the majority of these small thyroid cancers progress 
slowly or not at all, it is crucial to reassess the conventional 
management approach of immediate surgery for all PTCs.1,3,4 
Accordingly, the American Thyroid Association (ATA) stated 
that AS should be considered as an initial approach instead 
of definitive intervention in patients with low-risk PTMC, 
those at high operative risk because of comorbidity, and those 
with a short life expectancy.5
Although optimal criteria to define AS eligibility have not 
been agreed upon, most AS protocols rely primarily on initial 
tumor size, tumor extension, metastases, patient’s perspective, 
and even on the presence of supportive healthcare members. 
These candidates should be closely monitored via serial high-
resolution neck ultrasonography (US), physical examination, 
and/or other imaging studies during the follow-up while 
maintaining the option of definitive therapy for patients who 
are reclassified as patients with higher risk.6
However, in 2%–15% of patients deemed eligible for 
AS, tumor characteristics or extent may be underestimated, 
resulting in treatment delay and potentially compromising 
cure for patients with aggressive disease.7–13 However, no 
definite biological or clinical parameters currently exist to 
distinguish low-risk indolent PTMC from potentially aggres-
sive PTMC. Therefore, some patients initially eligible for 
AS could present disease progression such as lymph node 
metastasis (LNM), considering that is not possible to predict 
aggressive disease and AS is inadequate for these patients.
Because AS of low-risk PTMC has been validated in 
limited instances over short periods, there is currently little 
research on long-term oncologic outcomes. The present study 
compared the incidences of recurrence in patients with low-
risk PTMC initially eligible for AS regardless of LNM. By 
this approach, we could investigate the oncologic outcome 
of imitate delayed surgery after the detection of clinically 
apparent LNM during AS. To achieve our goal, we have 
assessed the oncologic outcomes of a large retrospective 
cohort of 5,348 patients with low-risk PTMC with a follow-
up of up to 25 years.
Materials and methods
study cohort
Between 1987 and 2016, a total of 18,404 consecutive 
patients diagnosed with PTMC underwent surgical treat-
ment at our hospital. We reviewed the medical records of 
these patients using the endocrine surgery database at Yonsei 
University College of Medicine. This study was approved 
by the Institutional Review Board, and the requirements 
for patient approval and informed consent were waived 
due to retrospective design of the study. The anonymous 
data were kept confidential, and only researchers of this 
study had a private access to the data. First, we excluded 
10,349 (56.2%) patients who underwent total thyroidec-
tomy (TT) and central compartment neck node dissection 
(CCND) with preoperative high-risk PTMC showing one 
or more aggressive clinical features such as neck irradia-
tion and family history of thyroid cancer. In addition, we 
excluded the patients who underwent TT with CCND due to 
therapeutic strategy such as postoperative radioactive iodine 
therapy based on the final pathologic stage (Figure 1). Of 
the remaining 8,055 patients, we identified 7,264 (39.4%) 
who underwent lobectomy with prophylactic CCND, our 
standard procedure for low-risk PTMC. Of them, 4,927 
(26.8%) patients (Group I) met the criteria for AS suggested 
by the thyroid cancer management team at Memorial Sloan 
Kettering Cancer Center.6 Among them, 781 (15.9%) were 
defined as ideal candidates and 4,146 (84.1%) as appropri-
ate candidates (Figure 1). We have also enrolled patients 
who met the criteria for consideration as a candidate for 
AS except clinically apparent LNM. In our study cohort, 
a total of 808 (4.4%) patients with PTMC underwent TT 
and modified radical neck dissection (MRND) due to lateral 
neck node metastasis. Of these, we excluded 387 (2.1%) 
patients with preoperatively detected extrathyroidal exten-
sion (ETE), T4 tumors, clinical apparent central LNM, 
and distant metastasis as inappropriate candidates for AS. 
Finally, the remaining 421 patients (Group II) met the AS 
criteria except clinically apparent LNM: 52 (12.4%) were 
ideal candidates, and 369 (87.6%) were appropriate can-
didates. Therefore, we postulated our patients divided into 
two groups imitating initial definite intervention (Group I) 
and delayed intervention after unfavorable nodal metastasis 
(Group II) (Figure 1). Postoperative pathological evaluation 
did not show any case with positive surgical margin.
Postoperative management and follow-up
After surgery, the patients who underwent TT with MRND 
underwent radioactive iodine ablation (100–200 mCi). 
We have regularly followed all patients by US and serum 
thyroglobulin testing at 6- or 12-month intervals to check 
for local recurrences. Each patient also had an annual chest 
X-ray or a computed tomography scan to detect potential 
lung metastases. Structural recurrent disease was defined as 
pathologically or cytologically proven recurrent or metastatic 
lesions and/or the appearance of metastatic lesions in other 
distant organs on imaging studies. In this study, because 
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most of patients underwent lobectomy initially, we did not 
consider recurrence if structural disease was not identified. 
Disease-free survival (DFS) was defined as the time interval 
from initial surgery to the detection of structural recurrent 
disease.
statistical analysis
Data were expressed as mean±SD or n (%) for descriptive 
statistics. A t-test was used for continuous variables. Pear-
son’s chi-squared test and Fisher’s exact test were used for 
categorical variables, appropriately. Kaplan–Meier survival 
analysis was used to estimate DFS. Statistical significance 
was set at P<0.05. Statistical analyses were performed using 
IBM SPSS statistics version 23.0 (SPSS Inc., Chicago, IL, 
USA), and R version 3.1.3 (http://www.R-project.org).
Results
Oncologic outcomes of study cohort
In Group I, 4,927 patients with low-risk PTMC, potential 
candidates for AS, underwent immediate lobectomy with 
prophylactic CCND (Figure 2). During follow-up period, 
48 (0.97%) patients of Group I showed structural recurrent 
disease. Nineteen (0.38%) patients underwent second-wave 
completion thyroidectomy with CCND and 29 (0.59%) 
patients underwent second-wave completion thyroidectomy 
with MRND, according to the level of LNM. In the case of 
Group II, 421 patients underwent TT with MRND (Group II). 
Twenty-two (5.2%) patients of Group II presented neck node 
recurrence followed by second-wave selective node dissec-
tion. The median follow-up period was 163 months (range, 
121–300 months).
Figure 1 Scheme of defining group indicating immediate surgery group of ideal or appropriate candidates for AS and delayed surgery imitating group of ideal or appropriate 
candidates for as except accompanying with clinically apparent lnM.
Abbreviations: AS, active surveillance; CCND, central compartment neck node dissection; ETE, extrathyroidal extension; LNM, lymph node metastasis; MRND, modified 
radical neck dissection; PTMC, papillary thyroid microcarcinoma; TT, total thyroidectomy.
Consecutive patients with PTMC underwent surgery in our retrospective cohort (N=18,404)   
Consecutive patients underwent  
lobectomy with prophylactic CCND 
(n=7,264)
Consecutive patients underwent 
TT with MRND 
(n=808)
TT with CCND
due to treatment strategy or high risk features
(n=10,349)
Exclusion:
Preoperative ETE:1,966
T4: 16
Clinically apparent 
central LNM: 1,485
Distant metastasis: 1
Exclusion:
Preoperative ETE:375
T4: 26
Preoperative bilaterality: 142
Distant metastasis: 4
Immediate surgery group (Group I)
(n=4,927)
Ideal candidates for AS: 781
Appropriate candidates for AS: 4,146
Delayed surgery imitating group (Group II) 
(n=421)
Ideal candidates for AS: 52
Appropriate candidates for AS: 369
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Comparisons of clinicopathological 
characteristics between group i and 
group ii
In addition to recurrence, the presence or absence of LNM 
produced remarkable clinical differences. Compared with 
Group I, Group II presented old age (46.1±8.7 vs 47.5±1.7 
years, respectively; P=0.001) and frequent male gender 
(18.2% vs 27.7%, respectively; P<0.001). Mean primary 
tumor size of Group II was larger than that of Group I 
(0.7±0.2 vs 0.5±0.2 cm, respectively; P<0.001). Multifocality 
(46.7% vs 10.1%, respectively; P<0.001) and microscopic 
ETE (57.7% vs 26.8%, respectively; P<0.001) were also 
frequently observed in Group II than in Group I. We also 
found obvious differences in other pathological staging char-
acteristics, including T-stage (P<0.001), N-stage (P<0.001), 
and tumor node metastasis (TNM) staging (P<0.001) between 
Groups I and II. Evaluation of lymph node ratio (LNR), 
defined as the number of metastatic lymph nodes (LNs) 
divided by the total number of LNs retrieved from the cen-
tral compartment (central LNR) and with nodes from lateral 
compartments (total LNR), showed that Group II tended to 
Figure 2 Flow chart presenting the oncologic outcomes of immediate surgery group and delayed surgery imitating group with low-risk PTMC potentially eligible for as.
Abbreviations: AS, active surveillance; CCND, central compartment neck node dissection; MRND, modified radical neck dissection; PTMC, papillary thyroid microcarcinoma; 
TT, total thyroidectomy.
Immediate surgery group (Group I)
(n=4,927)
Ideal candidates for AS: 781
Appropriate candidates for AS: 4,146
Delayed surgery imitating group (Group II) 
(n=421)
Ideal candidates for AS: 52
Appropriate candidates for AS: 369
No recurrence
(n=4,879)
Recurrence
(n=48)
Second-wave surgery group (Group III)
completion TT with MRND
(n=29)
Second-wave completion 
TT with CCND
(n=19)
No recurrence
(n=399)
Recurrence
(n=22)
Second-wave selective 
node dissection
(n=22)
have a higher central and total LNR than Group I (Table 1). 
During follow-up period as shown in Figure 2, structural 
recurrent disease was detected in 48 (0.9%) cases out of 
Group I and 22 (5.2%) cases out of Group II (P<0.001). Two 
patients of Group II died due to disease progression of distant 
metastasis; however, there was no disease-specific mortality 
in Group I (P=0.006). Using the Kaplan–Meier method, we 
found that 20-year DFS rates were significantly different 
between Groups I and II (P<0.001, Figure 3A).
impacts of second-wave completion 
thyroidectomy with MRnD on 
clinicopathological characteristics
We also evaluated the clinicopathological characteristics and 
oncologic outcomes of patients who underwent second-wave 
MRND due to lateral LN recurrence following initial immedi-
ate intervention (n=29) (Group III, a subgroup of Group I). 
There were still obvious differences between Group III and 
Group II in primary tumor size (0.6±0.3 vs 0.7±0.2 cm, 
respectively; P=0.001) and TNM staging (more frequent 
Stage IV in Group II, P<0.001), but other clinicopathological 
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findings showed no difference. During follow-up period, no 
recurrence after second-wave surgery and no fatal case were 
observed in Group III (Table 2). The DFS curve also showed 
that 20-year DFS rates were significantly different between 
Groups III and II (P=0.031, Figure 3B).
Discussion
Given the high prevalence of low-risk PTMC in the general 
population and its relative indolent nature, AS by special-
ized medical teams can be an evolving option in selected 
patients.4,14 Using the AS strategy developed in Kuma Hos-
pital in Japan, patients with low-risk PTMC with high-risk 
features such as locoregional invasion, distant metastasis, 
Table 1 Comparison of clinicopathological characteristics between patients with low-risk PTMC without lnM who underwent 
lobectomy with prophylactic CCnD (n=4,927) (group i) and patients with low-risk PTMC except clinically apparent lnM who 
underwent total thyroidectomy with MRnD (n=421) (group ii)
Group I Group II P-value
age (years), mean±sD 46.1±8.7 47.5±1.7 0.001
Male/female ratio 901/4,026 (18.2%/81.8%) 117/304 (27.7%/72.3%) <0.001
Tumor size (cm), mean±sD 0.5±0.2 0.7±0.2 0.001
Multifocality 496 (10.1%) 197 (46.7%) <0.001
Microscopic eTe 1,326 (26.8%) 243 (57.7%) <0.001
Central node metastasis
Retrieval ln
Central lnR
1,024 (20.7%)
4.8±3.7
0.11±0.03
308 (73.1%)
8.5±6.6
0.53±0.22
<0.001
<0.001
0.013
lateral node metastasis
Retrieval ln
lnR
Total lnR
–
–
–
0.11±0.03
421 (100%)
30.1±13.8
0.23±0.15
0.30±0.12
–
–
–
0.031
Pathologic type 0.017
Papillary 4,927 (100%) 421 (100%)
Classic
Follicular variant
4,752 (96.5%)
165 (3.3%)
401 (95.2%)
17 (4.1%)
Diffuse sclerosing 10 (0.2%) 3 (0.7%)
T stage
T1
T2
T3
T4
n stage
n0
n1a
n1b
TnM staging
stage i
stage ii
stage iii
stage iV
Distant metastasis
Recurrence
3,602 (73.1%)
2 (0.02%)
1,323 (26.7%)
0
3,903 (79.2%)
1,024 (20.7%)
0
4,114 (83.5%)
3 (0.001%)
810 (16.4%)
0
0
48 (0.9%)
179 (70.3%)
0
242 (37%)
0
0
0
421 (100%)
226 (53.6%)
0
12 (2.8%)
183 (43.4%)
2 (0.4%)
22 (5.2%)
<0.001
<0.001
<0.001
0.006
<0.001
Disease-specific mortality rate 0 2 (0.4%) 0.006
Abbreviations: CCnD, central compartment neck node dissection; eTe, extrathyroidal extension; ln, lymph node; lnM, lymph node metastasis; lnR, lymph node ratio; 
MRND, modified radical neck dissection; PTMC, papillary thyroid microcarcinoma; TNM, tumor node metastasis.
and signs of aggressive disease on high-quality US were 
excluded.2–4,15,16 Recently, ATA guidelines also introduced 
AS as an alternative strategy to immediate thyroid surgery 
in patients with very low-risk tumors, and patients are clas-
sified as ideal, appropriate, or inappropriate candidates for 
AS.5,6 To assess patients eligible for AS and medical team 
characteristics, initial and follow-up evaluations require serial 
neck US to evaluate the size and location of the thyroid cancer 
and the status of the cervical LNs.5,6 However, in 2%–15% 
of patients initially eligible for AS, imaging studies and fine-
needle aspiration cytology can underestimate tumor charac-
teristics or extent, resulting in treatment delay and potentially 
compromising cure for patients with aggressive disease.7–13
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In fact, AS strategy in low-risk PTMC has been suggested 
by a Japanese group based on single observational studies, 
and concerns remain about disease progression during AS, 
especially in patients with an aggressive phenotype.17–19 
Although AS has existed for approximately 10 years, it was 
only recently added to the international guidelines as a viable 
management strategy.5,14 One of the reasons for the delay 
was the persisting lack of long-term follow-up data from 
Figure 3 Comparison of disease-free survival according to patients’ group.
Notes: (A) Comparison of disease-free survival of patients with low-risk PTMC who underwent lobectomy with prophylactic central cervical node dissection (group i) with 
that of patients with low-risk PTMC except clinically apparent lymph node metastasis who underwent total thyroidectomy with modified radical neck dissection (Group II). 
(B) Comparison of disease-free survival of patients with second-wave surgery due to lateral ln recurrence (group iii, subgroup of group i) with that of group ii. P-value 
was determined by the log-rank test.
Abbreviation: PTMC, papillary thyroid microcarcinoma.
0 120 240 360
60D
is
ea
se
-fr
ee
 s
ur
vi
va
l (
%
)
D
is
ea
se
-fr
ee
 s
ur
vi
va
l (
%
)
80
100
Time (months)
0 120 240 360
Time (months)
Group I
A
roup I
Group II
0
60
80
100
0
Group III
Group II
Log-rank test, P<0.001 
Log-rank test, P=0.031
B
AS cohorts. Additionally, no comparative analysis has been 
performed to evaluate the long-term oncologic outcomes in 
patients with low-risk PTMC according to the timing of the 
surgery; immediate surgical intervention vs delayed surgery 
following clinically apparent LNM.
In this study, we aimed to generate imitating group of AS 
who underwent delayed surgery after detection of clinically 
apparent LNM with retrospective-based setting. In addition, 
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to understand the risk of delayed operation, we compared this 
imitating group (Group II) with immediate surgery group 
(Group I). Furthermore, we analyzed the oncologic outcome 
of second-wave surgery group because of local recurrence 
(Group III). Although this study has limitations because of 
its retrospective nature, to the best of our knowledge, our 
study provides the first evidence of large population-based 
long-term oncologic outcomes in 5,348 patients with low-risk 
PTMC who were initially eligible for AS.
In the comparison of baseline characteristics, we found 
remarkable difference between two groups (Group I vs Group 
II). In fact, according to the study design, Group I can be 
regarded as an immediate operated group without AS. And, 
Group II can be considered as delayed surgery group. The 
immediate intervention group presented striking favorable 
characteristics compared with delayed surgical interven-
tion group. Of note, recurrence and even disease-specific 
mortality were different between two groups. All these data 
consistently represent the risk of delayed surgery after the 
development of clinically apparent LNM.
The ability to identify patients with indolent PTMC 
without progressive disease earlier and more accurately 
is likely to result in improved oncologic outcome such as 
lower metastasis and lower disease recurrence. It would 
also offer reassurance to patients without higher-risk disease 
when determining AS candidates. Both improved imaging 
technology and molecular biomarkers show promise in this 
regard.7,20,21 Nevertheless, thus far, no definite biological or 
Table 2 Comparison of clinicopathological characteristics in patients with low-risk PTMC who underwent second-wave MRnD 
following initial immediate surgery (n=29) (group iii) and patients with low-risk PTMC except clinically apparent lnM who underwent 
total thyroidectomy with MRnD (n=421) (group ii)
Group II Group III P-value
age (years), mean±sD 47.5±1.7 47±9.7 0.652
Male/female ratio 117/304 (27.7%/72.3%) 7/22 (24.1%/75.9%) 0.526
Tumor size (cm), mean±sD 0.7±0.2 0.6±0.3 0.001
Multifocality 197 (46.7%) 18 (62%) 0.316
Microscopic eTe 243 (57.7%) 10 (34.4%) 0.067
Central node metastasis
Retrieval ln
Central lnR
308 (73.1%)
8.2±6.6
0.53±0.22
23 (79.3%)
8.2±1.9
0.51±0.32
0.663
0.876
0.352
lateral node metastasis
Retrieval ln
ln ratio
Total lnR
421 (100%)
30.1±13.8
0.23±0.15
0.30±0.12
29 (100%)
26.7±16.1
0.24±0.35
0.30±0.18
1.0
0.031
0.913
0.986
Pathologic type 0.592
Papillary 421 (100%) 29 (100%)
Classic
Follicular variant
401 (95.2%)
17 (4.1%)
27 (93.1%)
2 (6.8%)
Diffuse sclerosing 3 (0.7%) 0
T stage
T1
T2
T3
T4
n stage
n0
n1a
n1b
TnM staging
stage i
stage ii
stage iii
stage iV
Distant metastasis
Recurrence
179 (70.3%)
0
242 (37%)
0
0
0
421 (100%)
226 (53.6%)
0
12 (2.8%)
183 (43.4%)
2 (0.4%)
22 (5.2%)
19 (70.3%)
0
10 (37%)
0
0
0
29 (100%)
22 (75.9%)
0
6 (22.2%)
1 (3.7%)
1 (3.7%)
0
1.0
1.0
<0.001
0.182
0.021
Disease-specific mortality rate 2 (0.4%) 0 1.0
Abbreviations: ETE, extrathyroidal extension; LN, lymph node; LNM, lymph node metastasis; LNR, lymph node ratio; MRND, modified radical neck dissection; PTMC, 
papillary thyroid microcarcinoma; TnM, tumor node metastasis.
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clinical parameters are available that can distinguish low-risk 
from potentially aggressive thyroid cancer, and the long-term 
oncological effect of delayed initial intervention has not 
been evaluated. For example, if follow-up imaging studies 
find cancer progression during AS, immediate intervention, 
including radical thyroid surgery with MRND, should be 
performed. However, the long-term oncological outcomes 
in patients with LNM who underwent primary-wave MRND 
following delayed initial intervention compared with second-
wave MRND after initial immediate surgery have not been 
determined. In this study, the analysis of clinicopathological 
characteristics of second-wave surgery group (Group III) 
more strongly support our idea for the risk of delayed surgery. 
Although the patients of this group have to undergo repeated 
surgery, their oncologic outcome was more favorable than 
Group II. We believe that this difference is quite important 
because local recurrence presenting lateral LNM makes 
patients with same N1b stage but the oncologic outcome 
such as recurrence rate is still different. In fact, it may seem 
inappropriate to compare Groups II and III because of retro-
spective nature of this study. However, we have selected ideal 
or appropriate candidates for AS based on the preoperative 
characteristics of primary tumor, indicating that Group II is 
able to imitate disease progression group found by clinically 
apparent LNM. In this sense, although the comparison seems 
inappropriate, this comparison can reflect that there might 
be a risk of the delayed intervention group being found by 
LNM during AS.
This study might include some of patients with noninva-
sive follicular thyroid neoplasm with papillary-like nuclear 
features (NIFTP) by new WHO classification. However, the 
frequency of NIFTP was significantly lower in Asian series 
(1.6%) compared with that of Western countries (13.3%).22 
To overcome this limitation, precise pathologic evaluation 
will be needed in the future studies.
Conclusion
Some low-risk PTMCs can progress significantly during the 
delayed intervention period after AS. We found that patients 
initially eligible for AS who underwent delayed surgical 
intervention had more aggressive disease and unfavorable 
oncologic outcomes than those who underwent initial inter-
vention without AS. Considering the time point of MRND, 
patients who underwent primary-wave MRND following 
delayed initial intervention showed a significantly higher 
prevalence of recurrence and worse oncologic outcomes 
than those who underwent second-wave MRND after initial 
immediate surgery. Thus, additional prognostic factors to 
identify patients with an aggressive phenotype despite appar-
ently low-risk PTMC are essential.
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